Scholarlink

<p>Syphilis is a health priority targeted for elimination by 2030, yet its global epidemiology remains insufficiently characterized. The study analyzed data from 25,630 adults aged ≥ 15 years who underwent syphilis testing in Jordan at Biolab Diagnostic Laboratories during 2010–2025. Cross-sectional and retrospective cohort analyses were used to estimate prevalence, temporal trends, patterns of rapid plasma reagin (RPR) and <i>Treponema pallidum pallidum</i> hemagglutination assay (TPHA) reactivity, associated risk factors, and incidence rate. Syphilis prevalence (ever RPR- or TPHA-reactive) was 0.9% (95% CI: 0.8–1.0%) overall and only 0.08% (95% CI: 0.05–0.10%) among those tested for visa-related medical screening. RPR reactivity was 0.5% (95% CI: 0.4–0.6%), and among RPR-reactive individuals, 79.2% (95% CI: 65.0–89.5%) were TPHA-reactive within 30 days. Outpatient or walk-in visits, doctor referrals, and laboratory referrals showed substantially higher reactivity than visa-related medical screening, whereas sex, governorate, insurance status, and testing year showed no significant associations. Cumulative syphilis incidence was 0.18% (95% CI: 0.04–0.72%) after two years of follow-up, with an incidence rate of 0.92 per 1,000 person-years (95% CI: 0.23–3.68). Syphilis prevalence and incidence in Jordan are relatively low, but with no evidence of decline over 15 years, indicating limited progress toward elimination targets.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Syphilis epidemiology in Jordan: prevalence, incidence, and seroreversion from 15 years of laboratory-based data

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月14日

查看全文
  • Issa Abu-Dayyeh,
  • Hiam Chemaitelly,
  • Ahmad Al Tibi,
  • Mohammad Ghunaim,
  • Thaer Hasan,
  • Amid Abdelnour,
  • Laith J. Abu-Raddad

摘要

Syphilis is a health priority targeted for elimination by 2030, yet its global epidemiology remains insufficiently characterized. The study analyzed data from 25,630 adults aged ≥ 15 years who underwent syphilis testing in Jordan at Biolab Diagnostic Laboratories during 2010–2025. Cross-sectional and retrospective cohort analyses were used to estimate prevalence, temporal trends, patterns of rapid plasma reagin (RPR) and Treponema pallidum pallidum hemagglutination assay (TPHA) reactivity, associated risk factors, and incidence rate. Syphilis prevalence (ever RPR- or TPHA-reactive) was 0.9% (95% CI: 0.8–1.0%) overall and only 0.08% (95% CI: 0.05–0.10%) among those tested for visa-related medical screening. RPR reactivity was 0.5% (95% CI: 0.4–0.6%), and among RPR-reactive individuals, 79.2% (95% CI: 65.0–89.5%) were TPHA-reactive within 30 days. Outpatient or walk-in visits, doctor referrals, and laboratory referrals showed substantially higher reactivity than visa-related medical screening, whereas sex, governorate, insurance status, and testing year showed no significant associations. Cumulative syphilis incidence was 0.18% (95% CI: 0.04–0.72%) after two years of follow-up, with an incidence rate of 0.92 per 1,000 person-years (95% CI: 0.23–3.68). Syphilis prevalence and incidence in Jordan are relatively low, but with no evidence of decline over 15 years, indicating limited progress toward elimination targets.